Dr Reddy's divests two antibiotic brands Ciprolet and Levolet in Russia & CIS countries

Dr Reddy's said the divestment of brands from its non-core areas will allow the company to focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WogflDi
via IFTTT